Takara Bio Stock

Takara Bio EBITDA

Delisted·Jun 12, 2026

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Takara Bio (4974.T) as of Aug 12, 2026 is 3.29 B JPY. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 4.45 B JPY — a change of -26.09% (lower).

EBITDA

3.29 BJPY

YoY

-26.09%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Takara Bio is 2026 3.29 B JPY. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Takara Bio was 2025 4.45 B JPY. It decreases by -26.09% lower compared to the previous year.
Access this data via the Eulerpool API

Takara Bio Stock analysis

What does Takara Bio do? Takara Bio Inc is a Japanese biotechnology company that has been active in the medical and life science industry since its founding in 1967. The company is a strong player in the field of molecular biology and operates in several countries such as the USA, Europe, and Asia. Takara Bio Inc was established as an independent company in 1999, focusing exclusively on the production of molecular biology products. The company offers a wide range of products in the fields of research and diagnostics, including enzymes, PCR kits, vectors and plasmids, antibodies, proteins, and cell culture products. Takara Bio Inc is organized into two divisions: Life Science Research and Diagnostics. The Life Science Research division provides products and solutions for research and development in areas such as molecular biology, neuroscience, proteomics, and genomics. The Diagnostics division offers products and solutions for clinical diagnostics and drug development. Takara Bio Inc also specializes in the automation of molecular biology procedures and offers automated systems that can perform processes such as nucleic acid extraction, PCR, and sequencing. The company is committed to sustainability and environmental protection, adhering to strict environmental and quality standards in its production processes and implementing waste reduction and efficient resource utilization programs. Overall, Takara Bio Inc is a leading company in the field of molecular biology, offering a wide range of products and solutions for research and diagnostics, and has become a key player in the life science industry through its global expansion and ability to provide custom solutions. Takara Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Takara Bio stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Takara Bio is 3.29 B JPY in 2026.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Takara Bio changed from 4.45 B JPY to 3.29 B JPY, representing a -26.09% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Takara Bio since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Takara Bio historically and in real time.

Access this data via the Eulerpool API

Income Statement — Takara Bio

All Key Metrics — Takara Bio